{"id":"NCT01326962","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF","officialTitle":"Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-30","primaryCompletion":"2013-05-12","completion":"2013-05-12","firstPosted":"2011-03-31","resultsPosted":"2016-03-28","lastUpdate":"2017-08-16"},"enrollment":28,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Single Arm","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs) or anti-TNF. Patients will receive RoActemra/Actemra at a dose of 8 mg/kg (max 800 mg) intravenously every 4 weeks for a total of 6 infusions. Non-biologic DMARD therapy may be continued throughout the study. Anticipated time on study treatment is 24 weeks.","primaryOutcome":{"measure":"Disease Activity as Measured by Disease Activity Score 28 (DAS28)","timeFrame":"Up to 1 year","effectByArm":[{"arm":"Tocilizumab","deltaMin":5.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":4,"countries":["Saudi Arabia"]},"refs":{"pmids":["27236390"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":28},"commonTop":["Hypertension","Neutropenia","Low hemoglobin","Low red blood cells","Epistaxis"]}}